Composition for enhancing cool feeling of nasal cavity, application of composition and atomized essence

Abstract

The invention discloses a composition for enhancing cool feeling of a nasal cavity, application of the composition and atomized essence, and relates to the technical field of cooling agents. The composition for enhancing the cool feeling of the nasal cavity comprises a cooling agent, glucoside and an activating agent, wherein the activating agent comprises borneol and / or a phospholipid compound; wherein the glucoside comprises a hydrophilic group and a hydrophobic group; the phospholipid compound comprises at least one of lysophosphatidic acid, lysophosphatidylcholine, lysophosphatidylinositol, lysophosphatidylserine and phosphatidylinositol 4, 5 diphosphate. Glucoside is used for intercepting cooling agent molecules and increasing the exposure concentration of the cooling agent in the nasal cavity, so that the cool feeling strength of the nasal cavity is enhanced, borneol and / or phospholipid compounds are / is used as activating agents, the sensitivity of a cool feeling body is enhanced, and the cool feeling strength of the nasal cavity is further enhanced. The composition for enhancing the cool feeling of the nasal cavity can enhance the cool feeling of the nasal cavity in a targeted mode, and the problems that an existing cooling agent composition for atomized essence cannot target the nasal cavity, and the cool feeling intensity is low are solved.

Description

Technical Field

[0001] The present invention relates to the technical field of cooling agents, and particularly relates to a composition for enhancing nasal cavity cooling sensation, its application, and an atomized fragrance. Background Art

[0002] Cooling agents are a general term for a class of chemical substances that can produce a cooling effect and have weak medicinal properties. Commonly used ones include cooling agent WS-23 (N,2,3-trimethyl-2-isopropylbutyramide) and L-menthol, etc. They are often used in combination with atomized fragrances. After being atomized, they reach various parts of the respiratory tract through the oral cavity, enabling consumers to obtain a cooling sensation. However, when using a single cooling agent, there may be problems such as a rigid cooling sensation, irritation or strange smell, and the action site of the cooling sensation is limited. Compound multiple cooling agents to form a cooling agent composition can, to a certain extent, improve the cooling intensity and comfort. However, due to the long diffusion distance, the cooling agent rarely reaches the nasal cavity, which limits the cooling experience of consumers.

[0003] Therefore, there is still a need to develop a cooling agent for atomized fragrances that can targetedly provide nasal cavity cooling sensation. Summary of the Invention

[0004] The main object of the present invention is to propose a composition for enhancing nasal cavity cooling sensation, its application, and an atomized fragrance, aiming to solve the problems that the existing cooling agent composition for atomized fragrances cannot target the nasal cavity and has a low cooling intensity.

[0005] To achieve the above object, the present invention proposes a composition for enhancing nasal cavity cooling sensation. The composition for enhancing nasal cavity cooling sensation includes a cooling agent, a glycoside, and an activator. The activator includes borneol and / or a phospholipid compound; wherein:

[0006] The glycoside includes a hydrophilic group and a hydrophobic group;

[0007] The phospholipid compound includes at least one of lysophosphatidic acid, lysophosphatidylcholine, lysophosphatidylinositol, lysophosphatidylserine, and phosphatidylinositol 4,5-bisphosphate.

[0008] In one embodiment, the cooling agent includes at least one of L-menthol, L-menthone, piperitone, methyl acetate, lactate, isomenthone, isopulegol, L-menthone glycerol ketal, isopulegol acetate, monomenthyl succinate, camphor, 1,8-cineole, 1-diisopropylphosphorylnonane, linalool, hydroxycitronellal, cinnamaldehyde, allyl isothiocyanate, carvacrol, thymol, α-fenchone, ice element, cooling agent WS-3, cooling agent WS-5, cooling agent WS-10, cooling agent WS-12, cooling agent WS-14, cooling agent WS-23, and cooling agent WS-27; and / or,

[0009] The glycosides include at least one of rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside M, dulcoside A, epigallocatechin gallate-glucoside, epicatechin-glucoside, epigallocatechin-glucoside, epicatechin gallate-glucoside, catechin-glucoside, hesperidin, naringin, quercetin-3-glucoside, kaempferol-3-glucoside, glycyrrhizin, and mogroside; and / or,

[0010] The mass ratio of the cooling agent, glycoside, and activator is (2.0 - 4.0):(0.08 - 0.35):(0.001 - 0.03).

[0011] In one embodiment, the cooling agent includes L-menthol and cooling agent WS-3, and the mass ratio of L-menthol to cooling agent WS-3 is (0.1 - 0.5):(1.0 - 3.0).

[0012] In one embodiment, the cooling agent includes L-menthol, cooling agent WS-23, and cooling agent WS-27, and the mass ratio of L-menthol, cooling agent WS-23, and cooling agent WS-27 is (0.1 - 0.5):(1.0 - 3.0):(0.1 - 0.5).

[0013] In one embodiment, the glycosides include rebaudioside A and epicatechin-glucoside, and the mass ratio of rebaudioside A to epicatechin-glucoside is (0.05 - 0.1):(0.05 - 0.2).

[0014] In one embodiment, the glycosides include rebaudioside A, epicatechin gallate-glucoside, and hesperidin, and the mass ratio of rebaudioside A, epicatechin gallate-glucoside, and hesperidin is (0.02 - 0.5):(0.01 - 0.5):(0.02 - 0.5).

[0015] In one embodiment, the activator includes borneol and lysophosphatidic acid, and the mass ratio of borneol to lysophosphatidic acid is (0.01 - 0.2):(0.01 - 0.2).

[0016] In one embodiment, the activator includes borneol, lysophosphatidylserine, and phosphatidylinositol 4,5-bisphosphate, and the mass ratio of borneol, lysophosphatidylserine, and phosphatidylinositol 4,5-bisphosphate is (0.01 - 0.2):(0.01 - 0.2):(0.02 - 0.3).

[0017] The present invention provides an application of the described composition for enhancing nasal cooling sensation in enhancing nasal cooling sensation.

[0018] The present invention provides an atomized essence, and the atomized essence includes the composition for enhancing nasal cavity cool feeling described above.

[0019] In the technical solution of the present invention, the composition for enhancing nasal cavity cool feeling firstly uses an amphiphilic glycoside containing a hydrophilic group and a hydrophobic group to target and provide nasal cavity cool feeling. The hydrophilic group of the glycoside forms a complex hydrogen bond network with the sugar chain of mucin and water molecules in nasal mucus, and the hydrophobic group of the glycoside is affinity for relatively hydrophobic cooling agent molecules, so as to effectively intercept the cooling agent molecules passing through the nasal cavity, improve the exposure concentration of the cooling agent molecules, extend the perception time of the cooling receptor to the cooling agent molecules, and further enhance the cool feeling intensity and cool feeling durability in the nasal cavity. In addition, using borneol or a phospholipid compound as an activator can improve the sensitivity of TRPM8, which is beneficial to enhancing the nasal cavity cool feeling intensity. When using borneol and a phospholipid compound as activators at the same time, the lipophilicity of borneol is used to assist the transmembrane of the phospholipid compound, which can increase the fluidity of the cell membrane phospholipid bilayer, further enhance the motility of the TRPM8 channel protein in the cell membrane, and is beneficial to further improving the sensitivity of TRPM8 and further enhancing the nasal cavity cool feeling intensity. Detailed implementation manners

[0020] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all embodiments. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts shall fall within the protection scope of the present invention.

[0021] It should be noted that if there are directional indications (such as up, down, left, right, front, back,...) involved in the embodiments of the present invention, the directional indications are only used to explain the relative position relationship and movement conditions between components in a specific posture. If the specific posture changes, the directional indications will also change accordingly.

[0022] In addition, if the descriptions such as "first" and "second" are involved in the embodiments of the present invention, the descriptions of "first", "second", etc. are only for descriptive purposes and cannot be construed as indicating or implying their relative importance or implicitly indicating the quantity of the indicated technical features. Thus, the features defined with "first" and "second" may explicitly or implicitly include at least one such feature. In addition, if "and / or" or "and / or" appears throughout the text, its meaning includes three parallel scenarios. Taking "A and / or B" as an example, it includes scenario A, or scenario B, or the scenario where both A and B are satisfied simultaneously. In addition, the technical solutions between various embodiments can be combined with each other, but it must be based on the ability of those of ordinary skill in the art to implement. When the combination of technical solutions results in contradictions or cannot be implemented, it should be considered that such a combination of technical solutions does not exist and is not within the scope of protection required by the present invention.

[0023] Transient receptor potential (TRP) channels are widely distributed in sensory neurons and other types of cells and are involved in various sensory functions, including temperature perception, pain perception, and chemoreception. The main subfamilies of transient receptor potential (TRP) channels that are closely related to temperature sensation are TRPV (vanilloid receptor), TRPM (melatonin receptor), and TRPA (ankyrin repeat receptor), which are widely distributed in respiratory epithelial cells and sensory nerve endings.

[0024] Cooling agents are a general term for a class of chemical substances that can produce a cooling effect and have mild medicinal properties. Commonly used ones include cooling agent WS-23 (N,2,3-trimethyl-2-isopropylbutyramide) and L-menthol, etc. They are often used in combination with atomized fragrances. After being atomized, they reach various parts of the respiratory tract through the oral cavity, giving consumers a sense of coolness. Cooling agents cause cations (mainly calcium ions Ca 2+ ) to flow into the cell by stimulating multiple pathways. This ion flow causes a change in the ion concentration inside the cell, thereby causing depolarization of the cell membrane. When the depolarization reaches the coolness threshold, an action potential is triggered, transmitting the coolness signal to the central nervous system, thus making people perceive coolness.

[0025] However, using a single cooling agent may have problems such as a rigid cooling sensation, irritation or strange smell, and a limited site of action of the cooling sensation. Blending multiple cooling agents to form a cooling agent composition can interact through multiple TRP channels to jointly regulate the body's response, improving the cooling intensity and comfort to a certain extent. However, due to the long diffusion distance, the cooling agent still rarely reaches the nasal cavity. The passing speed of the cooling agent in the nasal cavity is also relatively fast, and the effective contact time with the nasal cavity is short, resulting in less cooling agent intercepted on the inner surface of the nasal cavity and making it difficult to reach the coolness threshold. Therefore, it is difficult to feel the coolness in the nasal cavity, which limits the coolness experience of consumers. Therefore, there is still a need to develop a cooling agent for atomized fragrances that can target and provide nasal coolness.

[0026] Nasal mucus is a complex liquid covering the surface of the nasal mucosa, mainly composed of water and mucin. Mucin is composed of proteins and oligosaccharide chains linked by covalent bonds, and the presence of a large number of sugar chains makes it highly hydrophilic.

[0027] In addition, the cool feeling depends on the transmembrane transfer of ions. The TRPM8 channel is sensitive to cold stimuli and is the main sensor of cold sensation. Endogenous phospholipids such as endogenous lysophospholipids are phospholipids synthesized by the organism itself, which can rapidly sensitize and activate the TRPM8 channel without temperature change, and this effect is achieved by directly interacting with the TRPM8 channel inside the cell membrane. However, exogenous phospholipids such as exogenous lysophospholipids and exogenous phosphatidylinositol 4,5-bisphosphate need to pass through the cell membrane from the outside because they are not produced by the cell itself, and exogenous phospholipids are amphiphilic, that is, they contain both hydrophilic and hydrophobic groups, resulting in a relatively slow process for them to enter the cell membrane and cannot act on the TRPM8 channel as quickly as endogenous phospholipids. Borneol can not only be used for resuscitating the patient from unconsciousness but also has strong lipophilicity. Since lipophilic substances can dissolve between phospholipid molecules, they are more likely to pass through the cell membrane.

[0028] Based on the above background, the present invention proposes a composition for enhancing nasal cool feeling, the composition for enhancing nasal cool feeling includes a cooling agent, a glycoside, and an activator, the activator includes borneol and / or a phospholipid compound; wherein:

[0029] The glycoside includes a hydrophilic group and a hydrophobic group;

[0030] The phospholipid compound includes at least one of lysophosphatidic acid (LPA), lysophosphatidylcholine (LPC), lysophosphatidylinositol (LPI), lysophosphatidylserine (LPS), and phosphatidylinositol 4,5-bisphosphate (PIP2).

[0031] In the technical solution of the present invention, first, an amphiphilic glycoside containing a hydrophilic group and a hydrophobic group is used to achieve targeted nasal cooling sensation. The hydrophilic group of the glycoside forms a complex hydrogen bond network with the sugar chain of mucin and water molecules in nasal mucus, and the hydrophobic group of the glycoside has an affinity for relatively hydrophobic cooling agent molecules, thereby effectively intercepting the cooling agent molecules passing through the nasal cavity, increasing the exposure concentration of the cooling agent molecules, prolonging the perception time of the cooling receptor to the cooling agent molecules, and further enhancing the cooling sensation intensity and duration in the nasal cavity. In addition, using borneol or phospholipid compounds as activators can improve the sensitivity of TRPM8, which is beneficial to enhancing the nasal cooling sensation intensity. When using borneol and phospholipid compounds as activators simultaneously, the lipophilicity of borneol can assist the transmembrane transport of exogenous phospholipids, increasing the fluidity of the cell membrane phospholipid bilayer, further enhancing the motility of the TRPM8 channel protein in the cell membrane, thereby improving the sensitivity of TRPM8 and achieving further enhancement of the nasal cooling sensation intensity.

[0032] It should be noted that the activator in the present invention refers to a substance that can enhance the sensitivity of TRPM8. Compared with other phospholipids related to the cell membrane, lysophospholipids and phosphatidylinositol 4,5-bisphosphate have strong hydrophilicity and are more likely to contact the membrane surface, improving the sensitivity of TRPM8. Therefore, in the technical solution of the present invention, phospholipid compounds such as lysophospholipids and phosphatidylinositol 4,5-bisphosphate are selected as activators, and the effect of enhancing the cooling sensation intensity is better.

[0033] It should be noted that the lysophospholipids include lysophosphatidic acid, lysophosphatidylcholine, lysophosphatidylinositol, and lysophosphatidylserine. The lysophospholipids involved in the present invention are derived from the modification of soybean phospholipids by phospholipase A1.

[0034] In the embodiments of the present invention, the cooling agent includes at least one of L-menthol, L-menthone, piperitone, methyl acetate, lactate, isomenthone, isopulegol, L-menthone glycerol ketal, isopulegol acetate, monomenthyl succinate, camphor, 1,8-cineole, 1-diisopropylphosphoryl nonane, linalool, hydroxycitronellal, cinnamaldehyde, allyl isothiocyanate, carvacrol, thymol, α-fenchone, icilin, cooling agent WS-3, cooling agent WS-5, cooling agent WS-10, cooling agent WS-12, cooling agent WS-14, cooling agent WS-23, and cooling agent WS-27.

[0035] The cooling agents of the present invention can be natural compounds or synthetic cooling agents. For example, L-menthol, L-menthone, piperitone, methyl acetate, menthyl lactate, isomenthone, isopulegol, L-menthone glycerin ketal, isopulegol acetate, and monomenthyl succinate are compounds extracted from mint or prepared from its derivatives, which have a cooling effect. Ice element, cooling agent WS-3, cooling agent WS-5, cooling agent WS-10, cooling agent WS-12, cooling agent WS-14, cooling agent WS-23, and cooling agent WS-27 are synthetic cooling agents that can provide a cooling sensation for different senses and have high potency.

[0036] External cold and heat stimuli are not only stimuli to a single channel, and multiple TRP channels can interact with each other to jointly regulate the body's response. For example, L-menthol, which has a strong effect on TRPM8, can slightly activate TRPV3, and thymol and camphor, which have obvious response signals to TRPV3, can also slightly activate TRPM8. Therefore, compared with a single cooling agent, combining multiple cooling agents or substances that may have a cooling sensation may obtain an enhanced cooling intensity. In some embodiments of the present invention, it is preferred to use two or more cooling agents to provide a cooling sensation. L-menthol has a strong cooling effect, good sensory properties, and extremely low toxic and side effects. In some embodiments of the present invention, L-menthol is used in combination with a synthetic cooling agent.

[0037] In the embodiments of the present invention, the glycosides include at least one of rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside M, dulcoside A, epigallocatechin gallate-glucoside, epicatechin-glucoside, epigallocatechin-glucoside, epicatechin gallate-glucoside, catechin-glucoside, hesperidin, naringin, quercetin-3-glucoside, kaempferol-3-glucoside, glycyrrhizin, and mogroside. The above glycosides are all from natural plant extracts, which are convenient for safe use and all have hydrophilic groups and hydrophobic groups. In actual use, one or a combination of the above can be selected.

[0038] In the embodiments of the present invention, the mass ratio of the cooling agent, glycoside, and activator is (2.0 - 4.0):(0.08 - 0.35):(0.001 - 0.03).

[0039] In atomized flavors, the dosage of cooling agents is generally 3% - 5%. Since some cooling agents themselves have a slight flavor, exceeding this range easily affects the overall aroma of the atomized flavor; being lower than this range results in insufficient cooling intensity. Glycosides usually have a high viscosity, poor fluidity in solutions, and are not easy to flow. Moreover, the solubility of glycosides in water or other solvents is limited, which affects their uniform distribution in the solution. Therefore, when the dosage of glycosides is too high, it is easy to clog the wick during atomization and block the atomizer; when the dosage of glycosides is too low, the effect of enhancing the nasal cooling intensity is not obvious. Adding too much borneol will cause the problem of too strong a flavor, and exceeding the range of lysophospholipids may lead to cytotoxicity. Setting the dosages of the cooling agent, glycoside, and activator within the above ranges can take into account the control of production costs, the production process of the product, product storage, sensory stability, and the requirement of enhancing the nasal cooling effect.

[0040] In an embodiment of the present invention, the cooling agent includes L-menthol and cooling agent WS-3, and the mass ratio of L-menthol to cooling agent WS-3 is (0.1 - 0.5):(1.0 - 3.0). The cooling agent can be a compound of two cooling agents. For example, it includes L-menthol and cooling agent WS-3. L-menthol is a natural compound extracted from mint plants, with a strong cooling effect, and can produce a cooling sensation in multiple parts such as the mouth, throat, and nasal cavity, providing an immediate and obvious cool feeling; cooling agent WS-3 is one of the commonly used cooling agents, with a strong cooling effect and a long duration. Combining L-menthol and WS-3 has a stronger cooling effect and a longer duration, and the cooling sensation can be felt in multiple parts. Setting the mass ratio of L-menthol to cooling agent WS-3 as (0.1 - 0.5):(1.0 - 3.0), within this range, the mass ratio of L-menthol to cooling agent WS-3 can be 0.1:1.0, 0.1:2.0, 0.1:3.0, 0.2:1.0, 0.2:2.5, 0.2:3.0, 0.3:1.0, 0.3:2.0, 0.3:2.8, 0.4:1.0, 0.4:2.5, 0.4:3.0, 0.5:1.0, 0.5:2.0, 0.5:3.0, and the interval values between any two endpoint values.

[0041] In an embodiment of the present invention, the cooling agent includes L-menthol, cooling agent WS-23, and cooling agent WS-27, and the mass ratio of L-menthol, cooling agent WS-23, and cooling agent WS-27 is (0.1-0.5):(1.0-3.0):(0.1-0.5). The cooling agent can also be a compound of three cooling agents, such as including L-menthol, cooling agent WS-23, and cooling agent WS-27. Cooling agent WS-23 and cooling agent WS-27 can provide a strong and efficient cooling sensation and act on multiple parts. The mass ratio of L-menthol, cooling agent WS-23, and cooling agent WS-27 is set to (0.1-0.5):(1.0-3.0):(0.1-0.5). Within this range, the mass ratio of L-menthol, cooling agent WS-23, and cooling agent WS-27 can be 0.1:1.0:0.1, 0.1:2.0:0.3, 0.1:3.0:0.5, 0.2:1.0:0.1, 0.2:2.0:0.3, 0.2:3.0:0.5, 0.3:1.0:0.1, 0.3:2.0:0.3, 0.3:3.0:0.5, 0.4:1.0:0.1, 0.4:2.0:0.3, 0.4:3.0:0.5, 0.5:1.0:0.1, 0.5:2.0:0.3, 0.5:3.0:0.5, and the interval values between any two endpoint values.

[0042] In an embodiment of the present invention, the glycoside includes rebaudioside A and epicatechin-glucoside, and the mass ratio of rebaudioside A and epicatechin-glucoside is (0.05-0.1):(0.05-0.2). The glycoside can be a compound of two glycosides, such as rebaudioside A and epicatechin-glucoside. The mass ratio of rebaudioside A and epicatechin-glucoside is set to (0.05-0.1):(0.05-0.2). Within this range, the mass ratio of rebaudioside A and epicatechin-glucoside can be 0.05:0.05, 0.05:0.15, 0.05:0.2, 0.08:0.05, 0.08:0.15, 0.08:0.2, 0.1:0.05, 0.1:0.15, 0.1:0.2, and the interval values between any two endpoint values.

[0043] In an embodiment of the present invention, the glycosides include rebaudioside A, epigallocatechin gallate-glucoside, and hesperidin, and the mass ratio of rebaudioside A, epigallocatechin gallate-glucoside, and hesperidin is (0.02 to 0.5):(0.01 to 0.5):(0.02 to 0.5). The glycosides can be a compound of three glycosides, such as rebaudioside A, epigallocatechin gallate-glucoside, and hesperidin. The mass ratio of rebaudioside A, epigallocatechin gallate-glucoside, and hesperidin is set to (0.02 to 0.5):(0.01 to 0.5):(0.02 to 0.5). Within this range, the mass ratio of rebaudioside A and epicatechin-glucoside can be 0.02:0.1:0.02, 0.02:0.2:0.3, 0.02:0.5:0.5, 0.2:0.1:0.02, 0.2:0.2:0.3, 0.2:0.5:0.5, 0.3:0.1:0.02, 0.3:0.2:0.3, 0.3:0.5:0.5, 0.4:0.1:0.02, 0.4:0.2:0.3, 0.4:0.5:0.5, 0.5:0.1:0.02, 0.5:0.2:0.3, 0.5:0.5:0.5, and the interval values between any two endpoint values.

[0044] In an embodiment of the present invention, the activator includes borneol and lysophosphatidic acid, and the mass ratio of borneol and lysophosphatidic acid is (0.01 to 0.2):(0.01 to 0.2). Within this range, the mass ratio of borneol and lysophosphatidic acid can be 0.01:0.015, 0.01:0.1, 0.01:0.2, 0.12:0.01, 0.12:0.1, 0.12:0.2, 0.2:0.01, 0.2:0.1, 0.2:0.2, and the interval values between any two endpoint values.

[0045] In an embodiment of the present invention, the activator includes borneol, lysophosphatidylserine, and phosphatidylinositol 4,5-bisphosphate, and the mass ratio of borneol, lysophosphatidylserine, and phosphatidylinositol 4,5-bisphosphate is (0.01-0.2):(0.01-0.2):(0.02-0.3). Within this range, the mass ratio of borneol, lysophosphatidylserine, and phosphatidylinositol 4,5-bisphosphate can be 0.02:0.1:0.02, 0.02:0.2:0.3, 0.02:0.5:0.5, 0.2:0.1:0.02, 0.2:0.2:0.3, 0.2:0.5:0.5, 0.3:0.1:0.02, 0.3:0.2:0.3, 0.3:0.5:0.5, 0.4:0.1:0.02, 0.4:0.2:0.3, 0.4:0.5:0.5, 0.5:0.1:0.02, 0.5:0.2:0.3, 0.5:0.5:0.5, and the interval values between any two endpoint values.

[0046] The present invention provides an application of the described composition for enhancing nasal cool feeling in enhancing nasal cool feeling.

[0047] Since the composition for enhancing nasal cool feeling can increase the nasal cool feeling and durability, it is used to solve the problems that the existing cool flavor agent composition for atomized fragrance cannot target the nasal cavity and has a low cool feeling intensity.

[0048] The present invention provides an atomized fragrance, and the atomized fragrance includes the described composition for enhancing nasal cool feeling. The atomized fragrance has all the technical solutions of the composition for enhancing nasal cool feeling, and thus has all the beneficial effects of the composition for enhancing nasal cool feeling. The present invention will not elaborate on them one by one here.

[0049] In an embodiment of the present invention, the atomized fragrance further includes 1,2-propanediol and glycerol. In the atomized fragrance, the mass fraction of the composition for enhancing nasal cool feeling is 3%-5%.

[0050] The following further elaborates on the technical solutions of the present invention in conjunction with specific embodiments. It should be understood that the following embodiments are only used to explain the present invention and are not used to limit the present invention.

[0051] Example 1

[0052] A composition for enhancing nasal cool feeling, in parts by mass, includes 0.2 parts of L-menthol, 1.8 parts of cool flavor WS-3, 0.1 part of rebaudioside A, 0.2 part of epicatechin-glucoside, 0.002 parts of borneol, and 0.005 parts of lysophosphatidic acid, wherein each part is 10 g.

[0053] Example 2

[0054] A composition for enhancing nasal cool feeling, by mass fraction, comprises 0.3 parts of L-menthol, 2.2 parts of cooling agent WS-3, 0.1 part of rebaudioside A, 0.05 part of epigallocatechin gallate-glucoside, 0.05 part of hesperidin, 0.002 part of borneol and 0.005 part of lysophosphatidic acid, wherein each part is 10 g.

[0055] Example 3

[0056] A composition for enhancing nasal cool feeling, by mass fraction, comprises 0.5 parts of L-menthol, 2.5 parts of cooling agent WS-3, 0.1 part of rebaudioside A, 0.05 part of epigallocatechin-glucoside, 0.001 part of borneol, 0.005 part of lysophosphatidylserine and 0.01 part of phosphatidylinositol 4,5-bisphosphate, wherein each part is 10 g.

[0057] Example 4

[0058] A composition for enhancing nasal cool feeling, by mass fraction, comprises 0.2 parts of L-menthol, 1.8 parts of cooling agent WS-23, 0.5 parts of cooling agent WS-27, 0.08 part of rebaudioside A, 0.1 part of epigallocatechin-glucoside, 0.005 part of borneol and 0.02 part of lysophosphatidic acid, wherein each part is 10 g.

[0059] Example 5

[0060] A composition for enhancing nasal cool feeling, by mass fraction, comprises 0.3 parts of L-menthol, 2.5 parts of cooling agent WS-23, 0.5 parts of cooling agent WS-27, 0.05 part of rebaudioside A, 0.1 part of epigallocatechin gallate-glucoside, 0.18 part of hesperidin, 0.008 part of borneol and 0.015 part of lysophosphatidic acid, wherein each part is 10 g.

[0061] Example 6

[0062] A composition for enhancing nasal cool feeling, by mass fraction, comprises 0.3 parts of L-menthol, 3.0 parts of cooling agent WS-23, 0.3 parts of cooling agent WS-27, 0.08 part of rebaudioside A, 0.12 part of epigallocatechin-glucoside, 0.005 part of borneol, 0.012 part of lysophosphatidylserine and 0.012 part of phosphatidylinositol 4,5-bisphosphate, wherein each part is 10 g.

[0063] Example 7

[0064] A composition for enhancing nasal cool feeling, by mass fraction, comprises 0.3 parts of L-menthol, 3.0 parts of cooling agent WS-23, 0.3 parts of cooling agent WS-27, 0.08 part of rebaudioside A, 0.005 part of borneol, 0.012 part of lysophosphatidylserine, wherein each part is 10 g.

[0065] Example 8

[0066] Compared with Example 5, the difference lies in that it does not contain borneol.

[0067] Example 9

[0068] Compared with Example 6, the difference lies in that it does not contain lysophosphatidylserine.

[0069] Example 10

[0070] An atomized essence, in terms of parts by mass, includes 4.6 parts of 1,2 - propanediol, 5 parts of glycerol, and 0.4 part of the composition for enhancing nasal cavity cool feeling in Example 1, wherein each part is 10 g.

[0071] Comparative Example 1

[0072] Compared with Example 1, the difference lies in that it does not contain rebaudioside A and epicatechin - glucoside.

[0073] Comparative Example 2

[0074] Compared with Example 2, the difference lies in that it does not contain borneol and lysophosphatidic acid.

[0075] Comparative Example 3

[0076] Compared with Example 3, the difference lies in that it does not contain rebaudioside A, epicatechin gallate - glucoside, and hesperidin.

[0077] Comparative Example 4

[0078] Compared with Example 6, the difference lies in borneol, lysophosphatidylserine, and phosphatidylinositol 4,5 - bisphosphate.

[0079] Comparative Example 5

[0080] Compared with Example 3, the difference lies in that it only contains L - menthol and cooling agent WS - 3, wherein the mass ratio of the L - menthol to the cooling agent WS - 3 is 0.2:1.8.

[0081] Performance Test

[0082] The compositions for enhancing nasal cavity cool feeling in Examples 1 - 9 and Comparative Examples 1 - 5 were respectively injected into the cartridges of the same batch of disposable Mesh core atomizing devices (disposable e - cigarettes), and the cool feeling intensity in the nasal cavity after atomization of the compositions for enhancing nasal cavity cool feeling in Examples 1 - 9 and Comparative Examples 1 - 5 was evaluated. The test steps are as follows:

[0083] Weigh 0.3 g of cooling agent WS - 23, add 4.7 g of 1,2 - propanediol and 5.0 g of glycerol, stir at room temperature until dissolved, and then inject it into the cartridge as the blank control group;

[0084] Weigh 0.03 g of L-menthol and 0.27 g of cooling agent WS-3, add 4.700 g of 1,2-propanediol and 5.000 g of glycerol, stir at room temperature until dissolved, and then inject into the cartridge to form 5 groups of comparative examples.

[0085] Weigh 0.3 g of nasal cavity cooling sensation enhancing composition according to the raw material ratios of Examples 1-9 and Comparative Examples 1-4 respectively, then add 5.000 g of glycerol, and make up to 10.000 g with 1,2-propanediol to form groups of Examples 1-9 and Comparative Examples 1-4.

[0086] Inject the nasal cavity cooling sensation enhancing compositions of the blank control group, Examples 1-9 of the present invention and Comparative Examples 1-5 into the same type of cartridges respectively. After waiting for 30 minutes for the wicking to be completed, evaluate.

[0087] Tissue evaluation method: Select 20 well-trained evaluators. Each evaluator first evaluates the blank control group as a benchmark, and then evaluates the samples of the example group and the comparative example group each time during aspiration, and scores the nasal cavity cooling sensation intensity and durability of the samples. The evaluation criteria for nasal cavity cooling sensation intensity are shown in Table 1, and the evaluation criteria for nasal cavity cooling sensation durability are shown in Table 2.

[0088] Table 1 Evaluation criteria for nasal cavity cooling sensation intensity

[0089] Nasal cavity cool feeling intensity Not cool Slightly cool Cool Very cool Extremely cool Score 0-10 11-20 21-30 31-50 51-100

[0090] Table 2 Evaluation criteria for nasal cavity cooling sensation durability

[0091] Nasal cavity cool feeling durability Short Moderate Durable Very durable Score 0-10 11-30 31-50 51-100

[0092] The evaluation results of nasal cavity cooling sensation intensity are shown in Table 3, and the evaluation results of nasal cavity cooling sensation durability are shown in Table 4.

[0093] Table 3 Evaluation results of nasal cavity cooling sensation intensity

[0094] Group Nasal cavity cool feeling intensity Blank control group 12 Example 1 group 18 Example 2 group 19 Example 3 group 17 Example 4 group 19 Example 5 group 23 Example 6 group 26 Example 7 group 21 Example 8 group 19 Example 9 group 20 Comparative example 1 group 14 Comparative example 2 group 16 Comparative example 3 group 16 Comparative example 4 group 18 Comparative example 5 group 7

[0095] Table 4 Evaluation results of nasal cavity cooling sensation durability

[0096]

[0097]

[0098] It can be seen from the test results in Table 3 and Table 4 that the group of Example 6 has better nasal cavity cooling sensation intensity and durability, and its composition is L-menthol, cooling agent WS-23, cooling agent WS-27, rebaudioside A, epicatechin-glucoside, borneol, lysophosphatidylserine and phosphatidylinositol 4,5-bisphosphate.

[0099] It can also be seen from the test results in Table 3 and Table 4 that the test results of the groups of Examples 1-9 are all better than those of the blank control group. The test results of the groups of Examples 1-3 are all better than those of the group of Comparative Example 5. Compared with the group of Comparative Example 5, the groups of Examples 1-3 reduced the dosage of the cooling agent, but could obtain a stronger and more lasting cooling sensation, indicating that the components other than the cooling agent have the effect of enhancing the cooling sensation intensity in the nasal cavity.

[0100] It can be known from the test results of the group of Example 1 and the group of Comparative Example 1, and the group of Example 3 and the group of Comparative Example 3 that when glycosides are not contained, the test results of the nasal cavity cooling sensation intensity and the nasal cavity cooling sensation durability become worse, indicating that the use of glycosides is beneficial to enhancing the nasal cavity cooling sensation intensity and improving the nasal cavity cooling sensation durability.

[0101] It can be known from the test results of the group of Example 2 and the group of Comparative Example 2, and the group of Example 6 and the group of Comparative Example 4 that when borneol and phospholipid compounds are not contained, the test results of the nasal cavity cooling sensation intensity and the nasal cavity cooling sensation durability become worse, indicating that the use of borneol and phospholipid compounds as activators is beneficial to enhancing the nasal cavity cooling sensation intensity and improving the nasal cavity cooling sensation durability.

[0102] It can be known from the test results of the group of Example 5 and the group of Example 8, and the group of Example 6 and the group of Example 9 that compared with the simultaneous use of borneol and phospholipid compounds as activators, the test results of the nasal cavity cooling sensation intensity and the nasal cavity cooling sensation durability are worse when only borneol or only phospholipid compounds are used, indicating that the effect of enhancing the cooling sensation by simultaneously using borneol and phospholipid compounds as activators is better than that of using borneol or phospholipid compounds alone as activators.

[0103] In summary, it can be known that the composition for enhancing the nasal cavity cooling sensation provided by the technical solution of the present invention can targetedly enhance the nasal cavity cooling sensation after atomization and effectively improve the durability of the cooling sensation, and can be used to enhance the nasal cavity cooling sensation, solving the problems that the existing cooling agent composition for atomized essence cannot target the nasal cavity and has a low cooling sensation intensity.

[0104] The above is only an exemplary embodiment of the present invention, and does not limit the patent scope of the present invention. Any equivalent structural transformation made using the content of the specification of the present invention under the technical concept of the present invention, or direct / indirect application in other related technical fields is included in the patent protection scope of the present invention.

Claims

1. A composition for enhancing the cooling sensation of the nasal cavity, characterized in that: The composition for enhancing the cooling sensation of the nasal cavity comprises a cooling agent, a glycoside and an activator, wherein the activator comprises borneol and / or a phospholipid compound; wherein: The glycoside includes a hydrophilic group and a hydrophobic group; The phospholipid compound includes at least one of lysophosphatidic acid, lysophosphatidylcholine, lysophosphatidylinositol, lysophosphatidylserine and phosphatidylinositol 4,5-bisphosphate.

2. The composition for enhancing the cooling sensation of the nasal cavity according to claim 1, characterized in that: The cooling agent comprises at least one of L-menthol, L-menthone, piperitone, menthyl acetate, menthyl lactate, isomenthone, isopulegol, L-menthone glycerol ketal, isopulegyl acetate, monomenthyl succinate, camphor, 1,8-cineole, 1-diisopropylphosphorylnonane, linalool, hydroxycitronellal, cinnamaldehyde, allyl isothiocyanate, carvacrol, thymol, α-fenchone, ice element, cooling agent WS-3, cooling agent WS-5, cooling agent WS-10, cooling agent WS-12, cooling agent WS-14, cooling agent WS-23 and cooling agent WS-27; and / or, The glycoside comprises at least one of rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside M, dulcoside A, epigallocatechin gallate-glucoside, epicatechin-glucoside, epigallocatechin-glucoside, epicatechin gallate-glucoside, catechin-glucoside, hesperidin, naringin, quercetin-3-glucoside, kaempferol-3-glucoside, glycyrrhizin and mogroside; and / or, The mass ratio of the cooling agent, glycoside and activator is (2.0-4.0): (0.08-0.35): (0.001-0.03).

3. The composition for enhancing the cooling sensation of the nasal cavity according to claim 2, characterized in that: The cooling agent comprises L-menthol and cooling agent WS-3, and the mass ratio of L-menthol to cooling agent WS-3 is (0.1-0.5): (1.0-3.0).

4. The composition for enhancing the cooling sensation of the nasal cavity according to claim 2, characterized in that: The cooling agent comprises L-menthol, cooling agent WS-23 and cooling agent WS-27, and the mass ratio of L-menthol, cooling agent WS-23 and cooling agent WS-27 is (0.1-0.5): (1.0-3.0): (0.1-0.5).

5. The composition for enhancing the cooling sensation of the nasal cavity according to claim 2, characterized in that: The glycoside comprises rebaudioside A and epicatechin-glucoside, and the mass ratio of the rebaudioside A to epicatechin-glucoside is (0.05-0.1):(0.05-0.2).

6. The composition for enhancing the cooling sensation of the nasal cavity according to claim 2, characterized in that: The glycosides include rebaudioside A, epicatechin gallate-glucoside and hesperidin, and the mass ratio of rebaudioside A, epicatechin gallate-glucoside and hesperidin is (0.02-0.5): (0.01-0.5): (0.02-0.5).

7. The composition for enhancing the cooling sensation of the nasal cavity according to claim 2, characterized in that: The activator comprises borneol and lysophosphatidic acid, and the mass ratio of the borneol to the lysophosphatidic acid is (0.01-0.2): (0.01-0.2).

8. The composition for enhancing the cooling sensation of the nasal cavity according to claim 2, characterized in that: The activator comprises borneol, lysophosphatidylserine and phosphatidylinositol 4,5-bisphosphate, and the mass ratio of the borneol, lysophosphatidylserine and phosphatidylinositol 4,5-bisphosphate is (0.01-0.2): (0.01-0.2): (0.02-0.3).

9. Use of the composition for enhancing the cooling sensation of the nasal cavity as claimed in any one of claims 1 to 8 in enhancing the cooling sensation of the nasal cavity.

10. An atomized flavor, characterized in that: The atomized flavor comprises the composition for enhancing the cooling sensation of the nasal cavity according to any one of claims 1 to 8.

Images